Oesophageal cancer: post-diagnosis statin use tied to increased survival

  • Lacroix O & al.
  • Cancer Causes Control
  • 28 Feb 2019

  • curated by Sarfaroj Khan
  • UK Clinical Digest
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • In patients with oesophageal cancer, post-diagnosis statin use is associated with a significant decrease in overall and cancer-specific mortality.

Why this matters

  • Several preclinical studies have shown that statins reduce cell growth and proliferation and increase apoptosis in oesophageal cancer.
  • Recent epidemiological studies have shown interesting results but suffered from limitations.

Study design

  • This observational, population-based used linked data of the Belgian Cancer Registry and included 5234 patients who were diagnosed with stage I to III oesophageal adenocarcinoma or squamous cell carcinoma from 2004-2014.
  • Statin use before and after oesophageal cancer diagnosis was evaluated.
  • Primary outcome was overall mortality.
  • Funding: None disclosed.

Key results

  • Of 5234 patients with stage I-III oesophageal cancer, 1628 (26%) were post-diagnostic statin users and 3606 (74%) were post-diagnostic non-statin users.
  • Post-diagnosis statin use was associated with a reduction in overall (adjusted HR [aHR], 0.84; P<.001 and cancer-specific mortality p=".01).">
  • After sensitivity and subgroup analysis, pre-diagnosis statin use was associated with decrease in overall (aHR, 0.84; 95% CI, 0.78-0.90) and cancer-specific (aHR, 0.82; 95% CI, 0.75-0.90) mortality.

Limitations

  • Some potentially important confounders were missing from the database.

Please confirm your acceptance

To gain full access to GPnotebook please confirm:

By submitting here you confirm that you have accepted Terms of Use and Privacy Policy of GPnotebook.

Submit